Curaleaf Holdings (CURLF) Gains from Investment Securities (2020 - 2023)

Curaleaf Holdings (CURLF) posted quarterly Gains from Investment Securities of $800000.0 for Q3 2023, down 51.4% on a QoQ basis from $1.6 million in Q4 2022.

Curaleaf Holdings (CURLF) Gains from Investment Securities (2020 - 2023) Analysis & Trends

Curaleaf Holdings (CURLF) has reported Gains from Investment Securities for 3 consecutive years, with $800000.0 the latest figure, recorded in Q3 2023.

  • Quarterly Gains from Investment Securities changed N/A year-over-year to $800000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2024 was -$24.5 million (changed N/A YoY) and the FY2020 annual result came in at -$37.6 million, changed N/A from the prior year.
  • Gains from Investment Securities eased to $800000.0 in Q3 2023 per CURLF's latest filing, from $1.6 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for CURLF reached as high as $1.6 million in Q4 2022 and fell as low as -$27.0 million in Q4 2020.
  • A 3-year average of -$8.2 million and a median of $800000.0 in 2023 frame the typical range for Gains from Investment Securities.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 89.28 Bn 87.42 Bn -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn
10 Curaleaf Holdings 6.95 Bn 6.95 Bn 157.29 Mn

Historic Data

Download Data
DateValue
Sep 30, 2023 800,000.00
Sep 30, 2023 800,000.00
Dec 31, 2022 1.65 Mn
Dec 31, 2022 1.65 Mn
Dec 31, 2020 -26.96 Mn
Dec 31, 2020 -26.96 Mn